|
About the WHITE PAPERS category
|
|
0
|
967
|
February 8, 2016
|
|
Stability chambers
|
|
3
|
1298
|
May 8, 2018
|
|
A Validation Approach for LIMS
|
|
2
|
1134
|
March 12, 2014
|
|
Writing Effective Test Scripts
|
|
2
|
1101
|
April 3, 2013
|
|
How to achieve international action on falsified and substandard medicines
|
|
0
|
1051
|
November 20, 2012
|
|
50 Acronyms of the FDA
|
|
0
|
946
|
November 11, 2012
|
|
Alternative SWD Models to the V-Model
|
|
0
|
993
|
June 14, 2012
|
|
Process validation latest guideline from USFDA
|
|
1
|
1131
|
March 21, 2012
|
|
Usfda guidelines
|
|
6
|
1608
|
March 10, 2012
|
|
Annex 11 Vs CFR's
|
|
2
|
1093
|
August 25, 2011
|
|
Latest guideline on SMF from PIC's
|
|
1
|
1111
|
July 25, 2011
|
|
Suppliar qualification latest guidelines from APIC
|
|
0
|
1066
|
May 31, 2011
|
|
Quality by Design for ANDA
|
|
5
|
1475
|
April 8, 2011
|
|
Link between sunlight and drug efficacy
|
|
0
|
957
|
March 16, 2011
|
|
CMO consolidation
|
|
0
|
974
|
March 15, 2011
|
|
Prequalification programme for selected APIs
|
|
0
|
828
|
March 12, 2011
|
|
$1.3bn average R&D cost per new drug
|
|
0
|
994
|
March 12, 2011
|
|
Cancer trials biggest risk for Pharmas
|
|
0
|
1087
|
February 19, 2011
|
|
Fda mapp
|
|
0
|
1009
|
February 18, 2011
|
|
Huge step Forward by EU
|
|
0
|
1061
|
February 18, 2011
|
|
Method Validation
|
|
0
|
1194
|
February 10, 2011
|
|
Residual solvents
|
|
0
|
1107
|
February 7, 2011
|
|
Forced Degredation Studies
|
|
0
|
985
|
February 7, 2011
|
|
GxP assessment form
|
|
4
|
2245
|
January 3, 2011
|
|
Retooling for Traceability: 10 Steps
|
|
0
|
921
|
December 25, 2010
|
|
Monographs Pharmacopoeias in Scribd
|
|
0
|
1511
|
December 16, 2010
|
|
Impurities in Pharmaceuticals
|
|
2
|
1096
|
December 9, 2010
|
|
Changes in European pharmacopoeia - Microbiology
|
|
0
|
1039
|
December 9, 2010
|
|
FDA launches global supply chain pilot scheme-News
|
|
0
|
979
|
December 3, 2010
|
|
Guidelines needed for inconsistent OTC medication -News
|
|
0
|
990
|
December 3, 2010
|
